Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 5 IN DEXTROSE 25 IN PLASTIC CONTAINER versus NEPHRAMINE 5 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 5 IN DEXTROSE 25 IN PLASTIC CONTAINER versus NEPHRAMINE 5 4.
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER vs NEPHRAMINE 5.4%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and nitrogen balance; dextrose provides caloric energy. Dextrose stimulates insulin release, promoting cellular uptake of amino acids.
Provides essential amino acids for protein synthesis in patients with renal impairment, reducing nitrogen waste accumulation.
Intravenous administration based on protein requirements: 1.0-2.0 g/kg/day amino acids, corresponding to 20-40 mL/kg/day of AMINOSYN II 5% in DEXTROSE 25%. Typical adult dose starts at 30-40 mL/hour, titrated to metabolic goals.
500 mL to 1000 mL intravenously over 8-24 hours, containing 5.4% amino acids, typically as a component of total parenteral nutrition; dose adjusted based on metabolic needs and protein requirements (usual 0.8-1.5 g/kg/day amino acids).
None Documented
None Documented
Not applicable as a single entity; amino acids have rapid plasma clearance (t1/2 of minutes to hours) and dextrose is rapidly cleared (t1/2 ~1-2 hours). Clinical context: Continuous infusion maintains steady state.
1-2 hours (endogenous amino acid pool turnover); clinical context: continuous infusion required to maintain plasma levels.
Amino acids are primarily metabolized; nitrogen is excreted as urea (renal, ~85%) and ammonia (renal, ~2-5%); glucose is fully metabolized to CO2 and water (exhaled and renal); electrolytes are excreted renally. Less than 5% excreted unchanged renally.
Renal: >90% as amino acids and metabolites. Biliary/fecal: negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution